All In Biotech

Drug Trial Radar · NCT05367765

A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Evaluating the Efficacy and Safety of Flumatinib Versus Imatinib for in Patients With Newly Diagnosed Chronic Myeloid Leukemia (CML)-in Chronic Phase (CP): A Multicenter, Open-label, Real World Study

Last checked: Nov 19, 2026Latest source record: May 10, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

2,400

Planned (sponsor's estimate)

Start

Apr 30, 2022

Primary completion

Apr 30, 2027

Study completion Apr 30, 2028

Sponsor

Sponsor type
Industry
First posted
May 10, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Flumatinib is an orally available TKI with high selectivity and potency against BCR-ABL1 kinase. It's a multi-center, open-label, real world study to explore the efficacy and safety of Flumatinib versus Imatinib as the first line therapy in patients with chronic myleiod leukemia(CML) in chronic phase(CP).

Conditions

  • CML, Chronic Phase

Interventions

  • FlumatinibDrug

    Flumatinib 600mg orally daily

  • ImatinibDrug

    Imatinib 400mg orally daily (Reference drug instructions)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Major molecular response (MMR) rate at 12 monthsTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Institute of Hematology and Oncology, Harbin The First Hospital

    Harbin, Heilongjiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.